Perspective Therapeutics (CATX) Common Equity (2011 - 2026)

Perspective Therapeutics' Common Equity history runs 16 years deep, the most recent figure standing at $347.4 million for Q1 2026.

• In Q1 2026, Common Equity rose 22.06% year-over-year to $347.4 million; the TTM figure through Mar 2026 stood at $347.4 million (up 22.06% YoY), while the FY2025 annual figure was $207.0 million, down 28.77% from the prior year.
• Common Equity came in at $347.4 million for Q1 2026 at Perspective Therapeutics, up from $207.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $347.4 million in Q1 2026 to a low of $54.6 million in Q4 2022.
• A 5-year average of $186.7 million and a median of $207.0 million in 2025 frame the typical range for Common Equity.
• Across the five-year window, Common Equity soared 286.63% in 2024 and retreated 28.77% in 2025, its largest moves.
• Perspective Therapeutics' Common Equity stood at $54.6 million in 2022, then soared by 37.58% to $75.2 million in 2023, then jumped by 286.63% to $290.7 million in 2024, then declined by 28.77% to $207.0 million in 2025, then jumped by 67.82% to $347.4 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $347.4 million, $207.0 million, and $242.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison